FMP
NewAmsterdam Pharma Company N.V.
NAMS
NASDAQ
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
26.23 USD
0.28 (1.07%)
About
ceo
Dr. Michael Harvey Davidson FACC, Facp., M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
CIK
0001936258
ISIN
NL00150012L7
CUSIP
N/A
Address
Gooimeer 2-35
Phone
31 35 206 2971
Country
NL
Employee
62
IPO Date
Feb 9, 2021
Key Executives
